Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.080
-0.040 (-1.89%)
At close: Jun 27, 2025, 4:00 PM
2.060
-0.020 (-0.96%)
After-hours: Jun 27, 2025, 7:55 PM EDT
Aytu BioPharma Revenue
Aytu BioPharma had revenue of $18.45M in the quarter ending March 31, 2025, with 31.57% growth. This brings the company's revenue in the last twelve months to $81.66M, up 0.41% year-over-year. In the fiscal year ending June 30, 2024, Aytu BioPharma had annual revenue of $81.00M, down -24.58%.
Revenue (ttm)
$81.66M
Revenue Growth
+0.41%
P/S Ratio
0.14
Revenue / Employee
$800,578
Employees
102
Market Cap
18.67M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 81.00M | -26.40M | -24.58% |
Jun 30, 2023 | 107.40M | 10.73M | 11.10% |
Jun 30, 2022 | 96.67M | 31.04M | 47.29% |
Jun 30, 2021 | 65.63M | 38.00M | 137.52% |
Jun 30, 2020 | 27.63M | 20.31M | 277.47% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AYTU News
- 3 days ago - Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) - Accesswire
- 5 days ago - Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - Accesswire
- 18 days ago - Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - Accesswire
- 22 days ago - Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - Accesswire
- 22 days ago - Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States - Accesswire
- 6 weeks ago - Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - Accesswire
- 7 weeks ago - Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - Accesswire